Page last updated: 2024-10-28

hydroxychloroquine and Chronic Hepatitis C

hydroxychloroquine has been researched along with Chronic Hepatitis C in 6 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Research Excerpts

ExcerptRelevanceReference
"The therapeutic effect of pegylated interferon (peg-IFN) alfa-2a combined with ribavirin (RBV) on chronic hepatitis C Egyptian patients is low and further efforts are required to optimize this therapy for achievement of higher rates of virological response."7.83Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. ( Abd-Ellah, MF; Eid, MS; Gad, MA; Helal, GK, 2016)
"The therapeutic effect of pegylated interferon (peg-IFN) alfa-2a combined with ribavirin (RBV) on chronic hepatitis C Egyptian patients is low and further efforts are required to optimize this therapy for achievement of higher rates of virological response."3.83Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. ( Abd-Ellah, MF; Eid, MS; Gad, MA; Helal, GK, 2016)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Molina-Iturritza, E1
San-José-Muñiz, I1
Ganchegui-Aguirre, M1
Balerdi-Sarasola, L1
Ortiz-de-Zárate-Ibarra, Z1
Gainzarain-Arana, JC1
Portu-Zapirain, J1
Cui, X1
Sun, J1
Minkove, SJ1
Li, Y1
Cooper, D1
Couse, Z1
Eichacker, PQ1
Torabi-Parizi, P1
Lin, KM1
Cheng, TT1
Lin, JC1
Chen, CJ1
Helal, GK1
Gad, MA1
Abd-Ellah, MF1
Eid, MS1
Yang, D1
Arkfeld, D1
Fong, TL1
Rizvi, R1
Hojjati, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349]Early Phase 1214 participants (Anticipated)Interventional2021-02-01Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for hydroxychloroquine and Chronic Hepatitis C

ArticleYear
Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
    Reviews in medical virology, 2021, Volume: 31, Issue:6

    Topics: Alphapapillomavirus; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; COVID-19;

2021

Other Studies

5 other studies available for hydroxychloroquine and Chronic Hepatitis C

ArticleYear
Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
    AIDS (London, England), 2020, 09-01, Volume: 34, Issue:11

    Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coinfe

2020
Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
    Clinical rheumatology, 2015, Volume: 34, Issue:6

    Topics: Adalimumab; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumato

2015
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
    Journal of medical virology, 2016, Volume: 88, Issue:12

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Genotype;

2016
Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection.
    The Journal of rheumatology, 2010, Aug-01, Volume: 37, Issue:8

    Topics: Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Carriers; Hepati

2010
Interferon-α induced lupus in a patient with chronic hepatitis C virus.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:3

    Topics: Antirheumatic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyd

2011
chemdatabank.com